Comparison of generic zidovudine + lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets.
Comparison of generic zidovudine + lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets.
复制标题
通用齐多夫定拉米夫定(Cipla,Duovir)和葛兰素史克品牌(Combivir)片剂的比较。
DOI:
10.1097/00126334-200404150-00012
复制
发表时间:
2004
期刊:
影响因子:
--
通讯作者:
Shet,Anita
中科院分区:
文献类型:
--
作者:
Henry,Keith;Brundage,Richard;Weller,Dennis;Akinsete,Omobosola;Shet,Anita
The HIV/AIDS epidemic has already killed an estimated 24 million people, with 40 million currently infected. Potent antiretroviral therapy can significantly improve the clinical course of HIV infection, but its use has been very limited due to its cost. Generic antiretroviral medications are available at a cost as low as 97% less than brand name drugs. 1 Recently, a patient returned to Minneapolis after initiating a course of generic zidovudine (AZT)+ 3TC (lamivudine)(Duovir, Cipla) overseas secondary to a possible sexual exposure to HIV. Evaluation revealed adverse effects attributable to the medications and a low risk for HIV transmission so treatment was discontinued.Because few data have been published regarding the purity of generic antiretroviral medications, an evaluation of the chemical purity of Duovir compared to Combivir (GlaxoSmithKline) was performed at the University of Minnesota Antiviral Pharmacology Laboratory. One tablet each of Combivir (AZT 300 mg+ 3TC 150 mg/capsule; Glaxo-Smith-Kline lot# 1ZP2346) and Duovir (AZT 300 mg+ 3TC 150 mg/capsule; Cipla lot# C10237) were analyzed for AZT and 3TC content using a procedure derived from United States Pharmacopeia (USP) guidelines for AZT tablets (USP 24-NF19). Solutions from analytical standards and each drug product were independently prepared to achieve final concentrations of 1.25 µg/mL for 3TC and 2.50 µg/mL for AZT. Highperformance liquid chromatographic
影响因子:
56.9
作者:
H. P. Binswanger
通讯作者:
H. P. Binswanger
DOI:
--
发表时间:
2001
期刊:
影响因子:
--
作者:
R. Gish
通讯作者:
R. Gish
DOI:
--
发表时间:
2001
期刊:
MMWR. Morbidity and mortality weekly report
影响因子:
--
作者:
S. Kukich
通讯作者:
S. Kukich